TLPH — TALPHERA, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1427925 ·
Last close
$0.80
Market Cap
$41.52M
52W High
$0.99
52W Low
$0.69
ADV30
141,210
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,948,000 | -2,556,000 | 30,155,000 | 3,823,000 | 11,677,000 |
| Dec 2025 | 0 | — | -3,453,000 | -3,772,000 | 29,719,000 | 5,894,000 | 12,684,000 |
| Sep 2025 | 1,000 | — | -3,422,000 | -4,436,000 | 30,742,000 | 3,457,000 | 11,565,000 |
| Jun 2025 | 0 | — | -3,693,000 | -3,489,000 | 16,515,000 | 6,791,000 | 9,888,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,364,000
Investing CF
$-14,345,000
Financing CF
$22,740,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.37
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-471,520,000
Inventory
—
Receivables
—
ST Investments
$14,487,000
EBIT TTM
$-14,363,000
Pretax Income TTM
$-14,363,000
Interest Exp TTM
$0
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,000
EBITDA
—
Free Cash Flow
$-5,777,500
Enterprise Value
$27,694,404
Total Cash
$21,108,000
Total Debt
$6,499,000
Shares Out
51,899,648
Trailing EPS
$-0.28
Book Value
$0.34
ROE
-118.4%
ROA
-40.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 28,000 | -13,484,000 | -14,290,000 | 29,719,000 | 12,684,000 | — | -11,364,000 |
| Dec 2024 | 0 | -15,252,000 | -13,004,000 | 18,236,000 | 10,235,000 | — | -12,683,000 |
| Dec 2023 | 651,000 | -16,889,000 | -18,397,000 | 20,395,000 | 6,290,000 | — | -17,492,000 |
| Dec 2022 | 0 | -20,352,000 | 47,755,000 | 47,487,000 | 25,673,000 | — | -28,331,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.25
Max Pain — expiry 2026-12-18
max pain strike: $1.00 · spot: $0.80 · call oi: 2,965 · put oi: 533
Expected Move to 2026-12-18:
±$1.00
(125.00%) —
implied range
$-0.20 –
$1.80
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RNXT | RenovoRx, Inc. | $41.30M | $0.92 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $40.93M | $0.97 | — |
| ZYBT | Zhengye Biotechnology Holding Ltd | $40.75M | $0.86 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $42.63M | $4.95 | — |
| KALA | KALA BIO, Inc. | $40.34M | $2.17 | — |
News headlines (Yahoo Finance, 1h cache)
Talphera, Inc. Q1 2026 Earnings Call Summary
2026-05-14 12:30 · Yahoo
Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...
2026-05-14 05:02 · Yahoo
Talphera Q1 2026 Earnings Call Transcript
2026-05-13 21:40 · Yahoo
Talphera (TLPH) Q1 2026 Earnings Transcript
2026-05-13 21:37 · Yahoo
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 20:05 · Yahoo
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
2026-05-07 20:05 · Yahoo
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
2026-03-25 12:30 · Yahoo
Talphera: Q4 Earnings Snapshot
2026-03-23 12:44 · Yahoo
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-23 12:30 · Yahoo
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
2026-03-18 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.